Drugs / Nifekalant
Nifekalant
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05169866 | May 2022 → May 2025 | atrial fibrillation | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03855826 | Jan 2019 → Jan 2020 | ventricular fibrillation, ventricular tachycardia | Sichuan Baili Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT04209959 | Jan 2019 → Jan 2020 | atrial fibrillation | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nifekalant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05169866 ↗ |
| Known as | NIF | “Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.” NCT03855826 ↗ |
| Known as | Nifekalant hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL360861 ↗ |
| Action | Inhibit | “It is a pure potassium channel blocker” NCT05169866 ↗ |
| Modality | Small molecule | — CHEMBL360861 ↗ |
| Route | Intravenous | “when intravenously infused” NCT03855826 ↗ |